Open Access

Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma

  • Authors:
    • Yi‑Xia Wang
    • Yan Huang
    • Xiao‑Ping Xu
    • Bo‑Bin Chen
    • Zhi‑Guang Lin
    • Yan Ma
    • Tian‑Ling Ding
    • Qian Wang
  • View Affiliations

  • Published online on: January 22, 2020     https://doi.org/10.3892/ol.2020.11328
  • Pages: 2097-2106
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to investigate the curative effect of high‑dose methotrexate (HD‑MTX) combined with teniposide (Vm26) vs. HD‑MTX alone in the treatment of primary central nervous system lymphoma (PCNSL), in order to provide data for assisting decisions associated with clinical treatment. Data from 56 patients with PCNSL admitted in Shanghai Huashan Hospital (Shanghai, China) from January 2009 to December 2014 were included into the present study. Clinical data, curative effects and prognosis of patients in these two groups were retrospectively analyzed using SPSS 20 statistical software. In the HD‑MTX+Vm26 group, 12 patients (42.85%) achieved complete remission (CR) and 10 patients (35.71%) achieved partial remission (PR), while in the HD‑MTX group 7 patients (25%) achieved CR and 11 patients (39.29%) achieved PR (P=0.158). The median progression‑free survival (PFS) time was 22 months in the HD‑MTX+Vm26 group and 12 months in the HD‑MTX group (P=0.019). The median overall survival time was 57 months in the HD‑MTX+Vm26 group, and 28 months in the HD‑MTX group (P=0.013). Compared with HD‑MTX alone, the combined treatment of HD‑MTX+Vm26 had an improved curative effect in the treatment of PCNSL, effectively controlled tumor progression in patients, prolonged survival time and improved prognosis. Age was an independent prognostic factor in patients with PCNSL. Patients with an age of ≤60 years exhibited longer PFS compared with patients with an age of >60 years.

Related Articles

Journal Cover

March 2020
Volume 19 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Wang, Y., Huang, Y., Xu, X., Chen, B., Lin, Z., Ma, Y. ... Wang, Q. (2020). Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma. Oncology Letters, 19, 2097-2106. https://doi.org/10.3892/ol.2020.11328
MLA
Wang, Y., Huang, Y., Xu, X., Chen, B., Lin, Z., Ma, Y., Ding, T., Wang, Q."Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma". Oncology Letters 19.3 (2020): 2097-2106.
Chicago
Wang, Y., Huang, Y., Xu, X., Chen, B., Lin, Z., Ma, Y., Ding, T., Wang, Q."Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma". Oncology Letters 19, no. 3 (2020): 2097-2106. https://doi.org/10.3892/ol.2020.11328